Defining typical appearance as a goal of health service provision is harmful and unnecessary for traits that are stigmatized but neither harmful nor distressing.
AMA J Ethics. 2021;23(7):E569-575. doi:
10.1001/amajethics.2021.569.
Eleftherios Mylonakis, MD and Panayiotis D. Ziakas, MD, MSc, PhD
Allocating resources for interventions requires consensus among stakeholders with a plurality of perspectives about how to weigh antimicrobial stewardship interventions’ risks and benefits.
AMA J Ethics. 2021;23(8):E631-638. doi:
10.1001/amajethics.2021.631.
Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021;23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Dr Charles Binkley joins Ethics Talk to discuss his article, coauthored with Michael Politz and Dr Brian Green: "Who, If Not the FDA, Should Regulate Implantable Brain-Computer Interface Devices?"
Elizabeth Boskey, PhD, MPH, MSSW, Amir Taghinia, MD, and Oren Ganor, MD
Training should be implemented to respond to clinical staff members’ concerns about trans patients occupying sex-segregated spaces and to help mitigate anti-trans bias.
AMA J Ethics. 2018;20(11):E1067-1074. doi:
10.1001/amajethics.2018.1067.
Clinicians can practice disability humility by developing social understandings of disability. This can help clinicians improve communication and express respect for patients’ authority about their experiences.
AMA J Ethics. 2018;20(12):E1181-1187. doi:
10.1001/amajethics.2018.1181